CLAIMS

1. Use of a compound that binds IL-13 and TSLP in the manufacture of a medicament for the treatment of a pulmonary disease in a subject, wherein said medicament reduces the level of fractional exhaled nitric oxide (FeNO) by at least 18 ppb compared to a control.
2. The use according to claim 1, wherein the medicament reduces the level of FeNO by at least 20 ppb, at least 30 ppb, or by at least 40 ppb, compared to a control.
3. The use according to any of the previous claims, wherein the pulmonary disease is asthma; optionally wherein the asthma is high eosinophilic asthma or low eosinophilic asthma.
4. The use according to any of the previous claims, wherein the control is baseline or wherein the control is placebo, optionally wherein baseline means the individual baseline of the subject.
5. The use according to any of the previous claims, wherein said reduction of FeNO level occurs within 4 weeks after the administration of the compound, wherein optionally said reduction of FeNO level occurs within 2 weeks after the administration of the compound, wherein optionally said reduction of FeNO level occurs within 1 week after the administration of the compound.
6. The use according to any of the previous claims, wherein the compound that binds IL-13 and TSLP is a polypeptide, such as an antibody or an antibody fragment.
7. The use according to claim 6, wherein the polypeptide comprises or consists of at least four ISVDs, wherein two ISVDs specifically bind IL-13 and two ISVDs specifically bind TSLP, wherein each of said at least four ISVDs comprises three complementarity determining regions (CDR1 to CDR3, respectively), wherein the at least four ISVDs are optionally linked via one or more peptidic linkers, and wherein: a first ISVD comprises:

    a CDR1 that is the amino acid sequence of SEQ ID NO: 7, a CDR2 that is the amino acid sequence of SEQ ID NO: 12 and a CDR3 that is the amino acid sequence of SEQ ID NO: 17,

a second ISVD comprises:

a CDR1 that is the amino acid sequence of SEQ ID NO: 8, a CDR2 that is the amino acid sequence of SEQ ID NO: 13 and a CDR3 that is the amino acid sequence of SEQ ID NO: 18,

a third ISVD comprises:

a CDR1 that is the amino acid sequence of SEQ ID NO: 9, a CDR2 that is the amino acid sequence of SEQ ID NO: 14 and a CDR3 that is the amino acid sequence of SEQ ID NO: 19, and

a fourth ISVD comprises:

a CDR1 that is the amino acid sequence of SEQ ID NO: 11, a CDR2 that is the amino acid sequence of SEQ ID NO: 16 and a CDR3 that is the amino acid sequence of SEQ ID NO: 21.

8. The use according to claim 6 or 7, wherein the polypeptide comprises or consists of the amino acid sequence of SEQ ID NO: 1.
9. The use according to any of the previous claims, wherein the subject has a baseline FeNO level of at least 50 ppb, and an eosinophil count of more than or equal to 0.3 $*10^9$ cells/L.
10. Use of a compound that binds IL-13 and TSLP in the manufacture of a medicament for the treatment of a pulmonary disease in a subject, wherein said medicament reduces the eosinophil count in blood by at least 30% compared to a control.
11. The use according to claim 10, wherein said reduction of the eosinophil count occurs within 4 weeks after the administration of the compound, wherein optionally said reduction of the eosinophil count occurs within 2 weeks after the administration of the compound, wherein optionally said reduction of the eosinophil count occurs within 1 week after the administration of the compound.
12. Use of a compound that binds IL-13 and TSLP in the manufacture of a medicament for the treatment of a pulmonary disease in a subject, wherein said medicament reduces airway inflammation.
13. The use according to claim 12, wherein said reduction of airway inflammation is characterized by a reduction of FeNO by at least 18 ppb, a reduction of eosinophil

count by at least 30% and/or an increase of the forced expiratory volume in one second (FEV1) by at least 0.07 L compared to a control;

wherein optionally said reduction of airway inflammation occurs within 4 weeks after the administration of the compound, wherein further optionally said reduction of airway inflammation occurs within 2 weeks after the administration of the compound, wherein optionally said reduction of airway inflammation occurs within 1 week after the administration of the compound.

14. Use of a compound which binds TSLP and/or IL-13 in the manufacture of a medicament for reducing the FeNO level in a subject, wherein the reduction of FeNO level prevents a loss of lung function.

15. The use according to claim 14, wherein said reduction of FeNO level is a reduction by at least 18 ppb; and/or

wherein said reduction of FeNO level is a reduction to a level below 25 ppb; and/or

wherein the subject has a baseline FeNO level of at least 50 ppb, at least 35 ppb, or at least 25 ppb; and/or

wherein the subject has a baseline FeNO level of at least 50 ppb, and an eosinophil count of more than or equal to 0.3 $*10^9$ cells/L; and/or

wherein the compound binds TSLP and IL-13; and/or

wherein said loss of lung function is linked to asthma.